RecruitingPhase 2NCT07196644

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification

Sponsor

AbbVie

Enrollment

100 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumors Harboring MET Amplification

Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Telisotuzumab Adizutecan for people with solid tumors harboring met amplification. The study is currently recruiting participants at 34 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTelisotuzumab Adizutecan

Intravenous (IV) Infusion

Locations(35)

Beverly Hills Cancer Center /ID# 275465

Beverly Hills, California, United States

City of Hope National Medical Center /ID# 275613

Duarte, California, United States

Valkyrie Clinical Trials /ID# 275547

Los Angeles, California, United States

Yale University School of Medicine /ID# 275978

New Haven, Connecticut, United States

Florida Cancer Specialists - North /ID# 277137

St. Petersburg, Florida, United States

Northwestern University Feinberg School of Medicine /ID# 276436

Chicago, Illinois, United States

University of Chicago Medical Center /ID# 275342

Chicago, Illinois, United States

START Midwest /ID# 276603

Grand Rapids, Michigan, United States

Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999

New York, New York, United States

Duke Cancer Institute /ID# 275604

Durham, North Carolina, United States

SCRI Oncology Partners /ID# 275686

Nashville, Tennessee, United States

Dell Seton Medical Center /ID# 276474

Austin, Texas, United States

UT Southwestern Medical Center /ID# 276053

Dallas, Texas, United States

The University of Texas MD Anderson Cancer Center /ID# 275663

Houston, Texas, United States

South Texas Accelerated Research Therapeutics (START) /ID# 276608

San Antonio, Texas, United States

Start Mountain Region /ID# 276607

West Valley City, Utah, United States

Virginia Cancer Specialists - Fairfax /ID# 276010

Fairfax, Virginia, United States

Rabin Medical Center. /ID# 274341

Petah Tikva, Central District, Israel

The Chaim Sheba Medical Center /ID# 274342

Ramat Gan, Tel Aviv, Israel

Tel Aviv Sourasky Medical Center /ID# 274344

Tel Aviv, Tel Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 274343

Jerusalem, Israel

Nagoya University Hospital /ID# 276336

Nagoya, Aichi-ken, Japan

National Cancer Center Hospital East /ID# 276298

Kashiwa-shi, Chiba, Japan

Kyushu University Hospital /ID# 276302

Fukuoka, Fukuoka, Japan

Hokkaido University Hospital /ID# 276333

Sapporo, Hokkaido, Japan

Kyoto University Hospital /ID# 276398

Kyoto, Kyoto, Japan

Tohoku University Hospital /ID# 276344

Sendai, Miyagi, Japan

Okayama University Hospital /ID# 276299

Okayama, Okayama-ken, Japan

National Cancer Center Hospital /ID# 276297

Chuo-Ku, Tokyo, Japan

Seoul National University Hospital /ID# 275703

Seoul, Seoul Teugbyeolsi, South Korea

Yonsei University Health System Severance Hospital /ID# 276184

Seoul, Seoul Teugbyeolsi, South Korea

Samsung Medical Center /ID# 275705

Seoul, Seoul Teugbyeolsi, South Korea

Clinica Universidad de Navarra - Pamplona /ID# 275503

Pamplona, Navarre, Spain

Hospital Universitario Vall de Hebron /ID# 275499

Barcelona, Spain

Hospital General Universitario Gregorio Maranon /ID# 275498

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07196644